EDIT Editas Medicine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EDIT

Price (delayed)

$7.46

Market cap

$514.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.21

Enterprise value

$416.94M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights
The debt has soared by 106% from the previous quarter and by 67% YoY
Editas Medicine's quick ratio has decreased by 46% YoY and by 41% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.editasmedicine.com
Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
68.97M
Market cap
$514.52M
Enterprise value
$416.94M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
25.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.15
Earnings
Revenue
$19.71M
EBIT
-$224.66M
EBITDA
-$218.32M
Free cash flow
-$181.45M
Per share
EPS
-$3.21
Free cash flow per share
-$2.64
Book value per share
$5.25
Revenue per share
$0.29
TBVPS
$7.49
Balance sheet
Total assets
$514.32M
Total liabilities
$153.64M
Debt
$43.95M
Equity
$360.68M
Working capital
$296.64M
Liquidity
Debt to equity
0.12
Current ratio
5.94
Quick ratio
5.81
Net debt/EBITDA
0.45
Margins
EBITDA margin
-1,107.5%
Gross margin
100%
Net margin
-1,118.3%
Operating margin
-1,146.3%
Efficiency
Return on assets
-39.2%
Return on equity
-50.3%
Return on invested capital
-62%
Return on capital employed
-49.5%
Return on sales
-1,139.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
0.54%
1 week
-10.87%
1 month
-17.66%
1 year
-60.63%
YTD
-15.9%
QTD
-15.9%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$19.71M
Gross profit
$19.71M
Operating income
-$225.95M
Net income
-$220.43M
Gross margin
100%
Net margin
-1,118.3%
EDIT's operating margin has dropped by 52% year-on-year and by 44% since the previous quarter
The net margin has contracted by 48% YoY and by 43% from the previous quarter
The revenue has declined by 23% since the previous quarter and by 23% year-on-year
Editas Medicine's gross profit has decreased by 23% from the previous quarter and by 23% YoY

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
1.42
P/S
25.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.15
EDIT's EPS is down by 13% year-on-year and by 9% since the previous quarter
EDIT's P/B is 71% below its 5-year quarterly average of 4.9 and 29% below its last 4 quarters average of 2.0
EDIT's equity is down by 35% year-on-year and by 13% since the previous quarter
The P/S is 51% less than the 5-year quarterly average of 52.7 and 26% less than the last 4 quarters average of 34.9
The revenue has declined by 23% since the previous quarter and by 23% year-on-year

Efficiency

How efficient is Editas Medicine business performance
The ROE has plunged by 56% YoY and by 22% from the previous quarter
Editas Medicine's ROA has decreased by 49% YoY and by 18% from the previous quarter
EDIT's return on sales is down by 49% year-on-year and by 42% since the previous quarter
EDIT's return on invested capital is down by 32% year-on-year and by 17% since the previous quarter

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
Editas Medicine's quick ratio has decreased by 46% YoY and by 41% QoQ
The current ratio has contracted by 45% YoY and by 41% from the previous quarter
The debt is 88% less than the equity
The company's debt to equity has surged by 140% QoQ and by 140% YoY
The debt has soared by 106% from the previous quarter and by 67% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.